Publications by authors named "Merrick Ross"

Claim this Profile
L
Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma.
Merve Hasanov, Simin Kiany, Marie-Andrée Forget, Roland Bassett, Michael A Davies, Merrick I Ross

Oncoimmunology· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surgical Reconstruction Toxicity Following Hypofractionated Adjuvant Radiation Therapy for Primary Cutaneous Melanoma.
Noel X Yang, Gianna L Rosamilia, Andrew J Arifin, Aya F Salem, Alison K Yoder, Merrick I Ross

Pract Radiat Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International Survey on Evidence for Index Lymph Node Surgery After Neoadjuvant Systemic Therapy for Stage III Melanoma.
Elan Novis, Mervi Rautalin, Rodabe N Amaria, Paolo A Ascierto, Christian U Blank, Merrick I Ross

Ann Surg Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma.
Elizabeth M Burton, Denái R Milton, Michael T Tetzlaff, Khalida Wani, Merrick I Ross, Rossana Lazcano

J Clin Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addendum: Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trial.
Emily K Ninmer, Hong Zhu, Kimberly A Chianese-Bullock, Margaret von Mehren, Naomi B Haas, Merrick I Ross

Nat Commun· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Prognostic Model for Patient Survival in Primary Anorectal Mucosal Melanoma: Stage at Presentation Determines Relevance of Histopathologic Features" [Modern Pathology 33 (2020) 496-513].
Priyadharsini Nagarajan, Jin Piao, Jing Ning, Laura E Noordenbos, Jonathan L Curry, Merrick I Ross

Mod Pathol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial.
Charles H Yoon, Merrick I Ross, Brian R Gastman, Jason J Luke, Paolo A Ascierto

Ann Surg Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable local control with hypofractionated radiation therapy for unresectable or metastatic melanoma.
Sydney A Keatts, Aya F Salem, David M Swanson, Ahsan S Farooqi, Andrew J Bishop, Merrick I Ross

Clin Transl Radiat Oncol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024.
Susan M Swetter, Douglas Johnson, Mark R Albertini, Christopher A Barker, Sarah Bateni, Merrick I Ross

J Natl Compr Canc Netw· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spitz melanocytic neoplasms with MLPH::ALK fusions: Report of two cases with previously unreported features and literature review.
Haneen T Salah, Richard K Yang, Sinchita Roy-Chowdhuri, Merrick I Ross, Phyu P Aung

J Cutan Pathol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vascular stenting of a malignant arterial blowout as a bridge to effective systemic and regional therapy.
Taylor P Williams, Mitchell W Cox, Bagi Jana, Merrick I Ross, Sarah B Fisher

J Surg Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trial.
Emily K Ninmer, Hong Zhu, Kimberly A Chianese-Bullock, Margaret von Mehren, Naomi B Haas, Merrick I Ross

Nat Commun· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Timing is Everything: Neoadjuvant Versus Adjuvant Immunotherapy in Patients with Resectable Metastatic Melanoma.
Ashley M Holder, Jennifer A Wargo, Merrick I Ross

Ann Surg Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary tumor site for localized Merkel cell carcinoma drives different management strategies without impacting oncologic outcomes.
Samuel Cass, Brandon Cope, Andrew J Bishop, Yi-Ju Chiang, B Ashleigh Guadagnolo, Merrick Ross

Radiother Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Timing is Everything: Neoadjuvant Versus Adjuvant Immunotherapy in Patients with Resectable Metastatic Melanoma.
Ashley M Holder, Jennifer A Wargo, Merrick I Ross

Ann Surg Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final 5-Year Follow-Up Results Evaluating Neoadjuvant Talimogene Laherparepvec Plus Surgery in Advanced Melanoma: A Randomized Clinical Trial.
Reinhard Dummer, David E Gyorki, John R Hyngstrom, Meng Ning, Tatiana Lawrence, Merrick I Ross

JAMA Oncol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Melanoma metastatic to the adrenal gland: An update on the role of adrenalectomy in multidisciplinary management.
Elliot A Asare, Sarah B Fisher, Yi-Ju Chiang, Lauren E Haydu, Sameer H Patel, Merrick I Ross

J Surg Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant therapy in high-risk, node-negative melanoma.
Merrick I Ross

Clin Adv Hematol Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Presence of Circulating Tumor Cells Predates Imaging Detection of Relapse in Patients with Stage III Melanoma.
Anthony Lucci, Sridevi Addanki, Yi-Ju Chiang, Salyna Meas, Vanessa N Sarli, Merrick I Ross

Cancers (Basel)· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial.
Jason A Chesney, Igor Puzanov, Frances A Collichio, Parminder Singh, Mohammed M Milhem, Merrick Ross

J Immunother Cancer· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.
Sapna P Patel, Megan Othus, Yuanbin Chen, G Paul Wright, Kathleen J Yost, Merrick I Ross, Kenneth F Grossmann

N Engl J Med· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma.
Rodabe N Amaria, Michael Postow, Elizabeth M Burton, Michael T Tetzlaff, Merrick I Ross

Nature· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.
Christopher P Vellano, Michael G White, Miles C Andrews, Manoj Chelvanambi, Russell G Witt, Merrick I Ross, Rossana Lazcano Segura

Nature· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma.
Joel Ho, Jane Mattei, Michael Tetzlaff, Michelle D Williams, Michael A Davies, Merrick Ross

Front Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma.
Robert H I Andtbacka, Yan Wang, Robert H Pierce, Jean S Campbell, Melinda Yushak, Merrick Ross

Cancer Res Commun· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis